BD2014138 EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY
- Write a review
€10.00
Tax included
Early stage breast cancer adjuvant chemotherapy
Dr. Carlos Garbino
Abstract
Adjuvant Chemotherapy for early stage breast cancer has substantive difficulties for a worldwide applicability due to important inequalities, in different countries and within the same country.
Governmental politics that provide economic support for health care systems should be implemented to solve these disparities that influence breast cancer care.
Important arguments for chemotherapy inclusion in the adjuvant setting are: Histologic Grade 3 tumors; Ki 67 higher than 14 %; Low Hormone Receptor status, less than 50 %; Positive HER 2 NEU status; Triple Negative status.
Microarrays technology is a new an important determination to be performed in patients with negative lymph nodes in an endocrine responsive tumor, in those countries whose economic facilities determine the availability of this procedure. In this setting, approved genetic testing such as ONCOTYPE DX, may be used to select chemotherapy in that subset of patients, if not already indicated due to HER 2 positivity or any other determinant factor, in an endocrine responsive cohort in order to determine the use of chemotherapy in addition to endocrine treatment.
Mammaprint is not yet recommended due to lack of predictive value.
According to the different mayor subtypes of breast cancer that had been identified, the following adjuvant chemotherapy treatment recommendations could be presented. (Annals of Oncology 22; 17136, 2011).
9782747222426
999 Items
New
16 other products in the same category:
Availability: 30 In Stock
Past ten years, literature is an increasing number of works trying to identify the different levers to operate to encourage innovation within companies. In continuation of this work focused on the emergence of a "culture of innovation," the state of the art made in this article allows us to bring about a feeling of "psychological safety" is the only means that:
- Members of the organization are not paralyzed by fear of failure and continue to offer bold initiatives,
- These players learn from the mistakes that will inevitably be committed during the innovation process and are able to no longer reproduce. We suggest, as such, some lines of thought to create a culture of "room for error" in organizations, starting with the consolidation of the reward and sanction systems by the inclination of the direction to "Legends" failures. We stress however that this may be possible in the context of American culture is not necessarily in that of French culture.
Availability: Out of stock
Availability: 30 In Stock